EMA/132888/2020

European Medicines Agency decision

P/0134/2020

of 15 April 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alpha1-proteinase inhibitor (human) (A1-PI) (EMEA-001312-PIP02-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0134/2020

of 15 April 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for alpha1-proteinase inhibitor (human) (A1-PI) (EMEA-001312-PIP02-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by CSL Behring GmbH on 15 July 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for alpha1-proteinase inhibitor (human) (A1-PI), powder and solvent for solution for injection / infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for alpha1-proteinase inhibitor (human) (A1-PI), powder and solvent for solution for injection / infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for alpha1-proteinase inhibitor (human) (A1-PI), powder and solvent for solution for injection / infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to CSL Behring GmbH, Emil-von-Behring-Strasse 76, 35041 – Marburg, Germany.

EMA/PDCO/688566/2019
Amsterdam, 28 February 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001312-PIP02-19

Scope of the application

Active substance(s):

Alpha1-proteinase inhibitor (human) (A1-PI)

Condition(s):

Prevention of graft versus host disease

Pharmaceutical form(s):

Powder and solvent for solution for injection / infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

CSL Behring GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, CSL Behring GmbH submitted for agreement to the European Medicines Agency on 15 July 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 August 2019.

Supplementary information was provided by the applicant on 22 November 2019. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Prevention of graft versus host disease (GVHD)

The waiver applies to:

- the paediatric population from birth to less than 28 days of age;
- powder and solvent for solution for injection / infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Prevention of graft versus host disease

2.1.1. Indication(s) targeted by the PIP

Prevention of acute GVHD (Grade II - IV) and of chronic GVHD in patients receiving an allogenic hematopoietic cell transplant (HCT) in combination with a standard immunosuppressive regimen

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection / infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.

Clinical studies	2	**Study 1 (CSL964_2001):** Double-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics, safety and efficacy of A1-PI in paediatric subjects from 12 to less than 18 years of age (and adults) undergoing allogeneic hematopoietic cell transplant (HCT) for haematological malignancies. **Study 2 (CSL964_XXX):** Open-label, single-arm, single dose trial to evaluate pharmacokinetics and safety of A1-PI in paediatric subjects from 28 days to less than 12 years of age undergoing allogeneic hematopoietic cell transplant (HCT).
Extrapolation, modelling and simulation studies	3	**Study 3 (CSL964_YYY):** Population PK modelling study to describe the pharmacokinetics of A1-PI in adolescent subjects from 12 to less than 18 years of age (and adults) undergoing allogeneic hematopoietic cell transplant (HCT) for haematological malignancies. **Study 4 (CSL964_ZZZ):** Population PK modelling study to describe the pharmacokinetics of A1-PI in paediatric subjects from 28 days to less than 12 years of age undergoing allogeneic hematopoietic cell transplant (HCT) for haematological malignancies. **Study 5 (CSL964_VVV):** Extrapolation study to support dose selection for use of A1-PI in paediatric subjects from 28 days to less than 12 years of age undergoing allogeneic hematopoietic cell transplant (HCT) for haematological malignancies.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By August 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes